Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine + Glulisine vs Premix in Diabetes
NCT00135941Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine and insulin glulisine in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Patient Reported Outcomes (Quality of Life, Treatment Satisfaction) at 24 months. Started Aug 2005; status: completed.
02
Drugs
insulin glargineinsulin glulisine
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00135941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135941.